Skip to main content
Premium Trial:

Request an Annual Quote

Celera Shares Fall as Earnings Miss Analyst Estimates

NEW YORK (GenomeWeb News) – Shares of Celera plummeted more than 20 percent today after the firm yesterday reported a loss for its fourth fiscal quarter and forecast lower revenue than analysts expected for 2009.

The company's shares were trading at $7.26 this afternoon, down 22 percent from yesterday's close of $9.34.

Celera yesterday reported revenues of $47.3 million for the three-month period ended Dec. 27, which was in line with analyst estimates.

However, the company's net loss of $6.1 million, or $.08 per share, for the quarter missed analysts' forecasts for a profit of $.01 per share.

The firm expects to bring in revenues of between $192 million and $202 million for fiscal-year 2009, as well as mid-single digit EPS on a non-GAAP basis for the year.

According to Thomson Reuters, analysts had expected a profit of $.19 per share for the year and $214.5 million in revenue.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.